FY2027 EPS Estimate for Mirum Pharmaceuticals Cut by Analyst

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Equities research analysts at HC Wainwright cut their FY2027 earnings estimates for Mirum Pharmaceuticals in a note issued to investors on Monday, January 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.04 for the year, down from their previous forecast of $0.86. HC Wainwright has a “Buy” rating and a $130.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ FY2028 earnings at $1.29 EPS and FY2029 earnings at $3.57 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The firm had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm’s revenue for the quarter was up 47.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.30) EPS.

MIRM has been the subject of several other research reports. Morgan Stanley raised their target price on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. TD Cowen restated a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, January 12th. Raymond James Financial restated a “strong-buy” rating and set a $110.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Finally, Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $104.92.

Mirum Pharmaceuticals Stock Up 2.4%

Shares of MIRM opened at $99.27 on Wednesday. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The business has a fifty day moving average of $78.36 and a 200 day moving average of $71.54. The company has a market cap of $5.10 billion, a PE ratio of -115.43 and a beta of 0.48. Mirum Pharmaceuticals has a 52-week low of $36.88 and a 52-week high of $99.44.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. MCF Advisors LLC grew its stake in Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Mirum Pharmaceuticals in the 3rd quarter worth approximately $33,000. Comerica Bank grew its position in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the last quarter. Quarry LP purchased a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at $41,000. Finally, CWM LLC raised its stake in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after acquiring an additional 161 shares during the last quarter.

Insider Activity

In other news, SVP Jolanda Howe sold 842 shares of the firm’s stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $80,991.98. Following the sale, the senior vice president directly owned 3,700 shares in the company, valued at approximately $355,903. This trade represents a 18.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Eric Bjerkholt sold 1,053 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $101,288.07. Following the transaction, the chief financial officer owned 43,741 shares of the company’s stock, valued at approximately $4,207,446.79. This trade represents a 2.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 32,429 shares of company stock worth $3,039,396 over the last ninety days. 22.87% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron bought 131,425 shares (~$9.0M at ~$68.48), increasing his stake by ~40% — a strong insider vote of confidence that can signal management conviction and attract investor interest. Read More.
• Positive Sentiment: HC Wainwright upgraded MIRM to Buy and raised its price target from $102 to $130, plus published an aggressive FY2030 EPS model — analyst optimism can boost allocation from research‑driven funds and support higher valuations. Read More.
• Positive Sentiment: Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare‑disease pipeline and global footprint — a strategic move that may be accretive to long‑term growth prospects. Read More.
• Positive Sentiment: Coverage and the upgrade pushed MIRM to a new 52‑week high, which can attract momentum/technical buyers and amplify the rally. Read More.
• Neutral Sentiment: Institutional holders show modest position changes across several funds (small buys/sells noted) — not large enough yet to indicate major shifts in ownership.
• Negative Sentiment: Several senior execs sold shares on the same day: CEO Christopher Peetz (6,831 sh), COO Peter Radovich (3,143 sh), CFO Eric Bjerkholt (1,053 sh) and SVP Jolanda Howe (842 sh). While the sizes are modest relative to total holdings, clustered insider sales can create near‑term concern about insider liquidity or tax/planning sales. Read More. Read More. Read More. Read More.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.